Source-grounded facts extracted from Bioventus Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Bioventus Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.
“The stockholders also ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 75,228,481 Shares for, 5,021 Shares against, 45,672 Shares abstaining, and no broker non-votes.”
Bioventus Inc. shareholders approved Election of Directors at the 2026-06-03 meeting.
“The following proposals were voted upon at the 2026 Annual Meeting and the final voting results with respect to each such proposal are set forth below. At the 2026 Annual Meeting, the stockholders elected the following directors to serve on the Company’s Board of Directors until the 2027 annual meeting of stockholders and until each such director’s respective successor is elected and qualified, or until each such director’s death, resignation or removal, based on the following votes: Nominee For Withheld Broker Non-Votes William A. Hawkins 67,405,961 1,128,994 6,744,219 John A. Bartholdson 68,365,980 168,975 6,744,219 Patrick J. Beyer 68,062,114 472,841 6,744,219 Robert E. Claypoole 68,360,467 174,488 6,744,219 Philip G. Cowdy 67,748,512 786,443 6,744,219 Ajay Dhankhar 68,459,149 75,806 6,744,219 Mary Kay Ladone 67,160,936 1,374,019 6,744,219 Michelle McMurry-Heath 68,073,685 461,270 6,744,219 Guido J. Neels 68,049,659 485,296 6,744,219 Guy P. Nohra 67,767,651 767,304 6,744,219 Susan M”
Bioventus Inc. reported three months ended March 28, 2026 results: revenue $132.1 million, net income $3.1 million, EPS $0.04 per diluted share. Guidance raised.
“For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.”
Bioventus Inc. reported Year ended December 31, 2025 results: revenue $568.1 million, net income $22.7 million, EPS $0.33.
“Full-Year 2025 Financial Results Bioventus’ full-year 2025 worldwide revenue totaled $568.1 million, a decrease of 0.9% compared to the prior-year period due to the divestiture of the Advanced Rehabilitation Business. On an organic* basis, revenue increased 7.5%, driven by above-market growth across all three businesses in the Company's portfolio. Full-year 2025 net income attributable to Bioventus was $22.7 million, compared to net loss attributable to Bioventus Inc. of $36.1 million in the prior-year period. Adjusted EBITDA* of $116.3 million increased 6.8% from $108.9 million last year due to strong organic* revenue growth and gross margin expansion. GAAP earnings of $0.33 per diluted share of Class A common stock improved from a loss of $0.56 per diluted share last year. Adjusted earnings per diluted share* was $0.68, reflecting a 21.4% increase compared to $0.56* * per diluted share in the prior-year period.”
Bioventus Inc. reported Three months ended December 31, 2025 results: revenue $157.9 million, net income $14.8 million, EPS $0.21.
“For the fourth quarter, worldwide revenue totaled $157.9 million, advancing 10.0% on an organic* basis driven by double-digit organic* growth across Pain Treatments and Surgical Solutions. Reported revenue increased 2.8% from $153.6 million in the prior-year period due to the impact of the prior-year divestiture of the Advanced Rehabilitation Business. Net income attributable to Bioventus Inc. was $14.8 million, compared to net loss attributable to Bioventus Inc. of $0.4 million in the prior-year period. Adjusted EBITDA* of $36.7 million advanced 30% from $28.3 million in the prior-year period as a result of higher organic* revenue growth, increased gross margin and disciplined spending. GAAP earnings of $0.21 per diluted share of Class A common stock improved from no income per share in the prior-year period. Adjusted Earnings Per Share (Adjusted EPS)* of Class A common stock of $0.24 per diluted share compares to $0.26** per diluted share in the prior-year period as improved operatin”
Bioventus Inc. incurred credit facility of a $100 million revolving credit facility and a $300 million first lien term loan A facility with Wells Fargo Bank, National Association at Term SOFR plus a margin of 2.50% maturing July 31, 2030.
“On July 31, 2025 (the “Closing Date”), Bioventus LLC, a Delaware limited liability company and subsidiary of Bioventus Inc. (“Bioventus LLC” or the “Company”) and certain of its subsidiaries entered into a Credit Agreement (the “2025 Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, and the lenders and other financial institutions party thereto. Pursuant to the 2025 Credit Agreement, the Company entered into a $100 million revolving credit facility (the “Revolving Credit Facility”) and a $300 million first lien term loan A facility (the “Term Loan Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”).”
Bioventus Inc. completed a disposition involving Rehab Acquisition Corporation, III (now known as Bioness Medical, Inc.) for $25.0 million (closed 2024-12-31).
“On December 31, 2024 , the Transaction closed (the “Closing”) and the Sellers received a cash payment of $25.0 million subject to customary post-closing adjustments for working capital.”
Bioventus Inc. reported full-year 2024 results: revenue $535 million to $550 million, EPS $0.25 to $0.33. Guidance raised.
“Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects: • Net sales of $535 million to $550 million—An increase of $15 million from previous guidance • Adjusted EBITDA* of $94 million to $99 million—An increase of $5 million from previous guidance • Non-GAAP EPS* of $0.25 to $0.33—An increase of $0.13 from previous guidance”
Bioventus Inc. reported three months ended March 30, 2024 results: revenue $129.5 million, net income net loss from continuing operations of $6.0 million, EPS Loss per share of Class A common stock from continuing operations was $0.07.
“For the first quarter, worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period. On an organic* basis, revenue increased 15.3%, driven by growth in Pain Treatments and Surgical Solutions. The Company also reported a first quarter net loss from continuing operations of $6.0 million, compared to a net loss from continuing operations of $100.0 million in the prior-year period. Adjusted EBITDA* from continuing operations totaled $22.6 million, advancing 33.5%, compared to the prior year total of $17.0 million due to strong revenue growth and increased gross margin. Loss per share of Class A common stock from continuing operations was $0.07 in the first quarter, compared to a loss of $1.28 in the prior-year period.”
Bioventus Inc. reported Full Year 2024 results: revenue $520 million to $535 million, EPS $0.12 to $0.20. Guidance initiated.
“Bioventus introduced its financial guidance for full-year 2024. The Company expects: • Net sales of $520 million to $535 million • Adjusted EBITDA* of $89 million to $94 million • Non-GAAP EPS* of $0.12 to $0.20”
Bioventus Inc. reported Full Year 2023 results: revenue $512.3 million, net income net loss of $121.2 million, EPS ($1.54) loss per share.
“Bioventus’ full-year 2023 worldwide revenue totaled $512.3 million, which was even compared to the prior year. On an organic* basis, revenue increased 3.6%, driven by 9.4% growth in Surgical Solutions. The Company also reported a full-year 2023 net loss from continuing operations of $121.2 million, compared to net loss from continuing operations of $144.7 million in the prior year. Adjusted EBITDA from continuing operations* of $88.9 million advanced 29.5% from $68.6 million last year due to disciplined cost management and savings from a corporate restructuring implemented at the beginning of the year. Loss per share of Class A common stock from continuing operations was $1.54 per share, compared to a loss of $1.70 per share last year.”
Bioventus Inc. reported Fourth Quarter 2023 results: revenue $135.4 million, net income net loss of $7.7 million, EPS ($0.10) loss per share.
“For the fourth quarter, worldwide revenue totaled $135.4 million, an increase of 7.6% compared to the prior year. On an organic* basis, revenue increased 14.3%, driven by more than 20% growth in Pain Treatments and Surgical Solutions. The Company also reported a fourth quarter net loss from continuing operations of $7.7 million, compared to net loss from continuing operations of $35.4 million in the prior-year period. Adjusted EBITDA* from continuing operations of $22.0 million advanced 28.1% from $17.2 million last year due to strong revenue growth and disciplined cost management. Loss per share of Class A common stock from continuing operations was $0.10 per share, compared to a loss of $0.40 per share last year.”
Bioventus Inc. amended Amendment No. 5 to the Credit and Guaranty Agreement with Wells Fargo Bank, National Association valued at Amended financial covenants: maximum debt leverage ratio from 5.65:1 to 4.00:1 over testing periods; (effective 2024-01-18).
“On January 18, 2024 (the “Closing Date”), Bioventus LLC (“Bioventus LLC”), a Delaware limited liability company and subsidiary of Bioventus Inc. (together with its subsidiaries, the “Company”) and certain of its subsidiaries entered into an Amendment No. 5 to the Credit and Guaranty Agreement (the “Fifth Amendment”) with Wells Fargo Bank, National Association, as administrative agent and collateral agent, and the lenders and other financial institutions party thereto, which amended the Credit and Guaranty Agreement, dated as of December 6, 2019 (the “2019 Credit Agreement,” and, as amended by that certain Amendment No. 1 to Credit and Guaranty Agreement, dated as of August 29, 2021, by the Second Amendment to Credit and Guaranty Agreement, dated as of October 29, 2021, by the Third Amendment to Credit and Guaranty Agreement, dated as of July 11, 2022, by the Fourth Amendment to Credit and Guaranty Agreement, dated as of March 31, 2023 and by the Fifth Amendment, the “Amended 2019 Credi”
Robert E. Claypoole was appointed as President and Chief Executive Officer at Bioventus Inc..
“As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.”
Anthony P. Bihl III departed as Interim President and Chief Executive Officer at Bioventus Inc..
“As previously reported, Robert E. Claypoole succeeded Mr. Bihl as President and Chief Executive Officer of the Company on January 10, 2024.”
Anthony P. Bihl III departed as Interim President and Chief Executive Officer at Bioventus Inc..
“succeeding Anthony P. Bihl III, the Company’s current Interim President and Chief Executive Officer, in such roles.”
Robert E. Claypoole was appointed as Class III Director at Bioventus Inc..
“and as a Class III director of the Company”
Robert E. Claypoole was appointed as President and Chief Executive Officer at Bioventus Inc..
“Robert E. Claypoole has been appointed as the Company’s President and Chief Executive Officer, and as a Class III director of the Company, effective January 10, 2024”
Bioventus Inc. reported the three and nine months ended September 30, 2023 results: revenue $120.8 million, net income Net Loss from continuing operations of $8.8 million, EPS Loss per share of Class A common stock from continuing operations of $0.12. Guidance raised.
“a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: • Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million,”
Bioventus Inc. reported twelve months ending December 31, 2023 results: revenue $490 million to $505 million, EPS ($0.24) to ($0.20). Guidance initiated.
“For the twelve months ending December 31, 2023, the Company expects: • Net sales of $490 million to $505 million • Adjusted EBITDA* of $75 million to $80 million • Non-GAAP EPS* of ($0.24) to ($0.20)”
Bioventus Inc. reported three and six months ended July 1, 2023 results: revenue $137.1 million, net income $4.7 million, EPS $0.06. Guidance initiated.
“a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: • Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or”
Bioventus Inc. shareholders approved Approval of the 2023 Plan.
“The stockholders also approved the 2023 Plan described in”
Bioventus Inc. shareholders approved Election of Class II Directors.
“Nominee For Withheld Broker Non-Votes John A. Bartholdson 59,864,373 977,795 8,674,061 Patrick J. Beyer 58,954,599 1,887,569 8,674,061 William A. Hawkins 58,254,590 2,587,578 8,674,061 Mary Kay Ladone 58,552,359 2,289,809 8,674,061 Susan M. Stalnecker 58,586,174 2,255,994 8,674,061”
Bioventus Inc. completed a disposition involving LifeNet Health for $35.0 million (closed 2023-05-22).
“On May 22, 2023 , the Transaction closed (the “Closing”) and the Sellers received a cash payment of $35.0 million subject to customary post-closing adjustments for working capital.”
Bioventus Inc. reported three months ended April 1, 2023 results: revenue $119.1 million, net income $100.0 million, EPS $1.28. Guidance reaffirmed.
“Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023. Q1 Financial Summary: • Net Sales of $119.1 million, up $1.8 million, or 1.5%, year-over-year as reported (1.9% constant currency*) • Net Loss from continuing operations of $100.0 million, compared to Net Loss from continuing”
Bioventus Inc. entered into Asset Purchase Agreement with LifeNet Health valued at $35,000,000 (effective 2023-05-10).
“On May 10, 2023, Bioventus LLC (“BV LLC”), a subsidiary of Bioventus Inc. (the “Company”), together with two of its subsidiaries, Misonix, LLC (“Misonix”) and Solsys Medical, LLC (“Solsys,” and together with BV LLC and Misonix, the “Sellers”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with LifeNet Health (the “Buyer”), pursuant to which the Buyer agreed to: (i) acquire all assets of the Sellers related to the Sellers’ business of developing, marketing and distributing the TheraSkin Product and the TheraGenesis Product”
Bioventus Inc. reported the quarter ended April 1, 2023 results: revenue approximately $119 million.
“At this time, the Company expects to report revenue for the quarter ended April 1, 2023, of approximately $119 million and Adjusted EBITDA of approximately $17 million.”
Anthony P. Bihl III was appointed as Class III director at Bioventus Inc..
“On April 4, 2023, Anthony P. Bihl III was appointed as Interim Chief Executive Officer of the Company and as a Class III director of the Company, effective April 5, 2023.”
Anthony P. Bihl III was appointed as Interim Chief Executive Officer at Bioventus Inc..
“On April 4, 2023, Anthony P. Bihl III was appointed as Interim Chief Executive Officer of the Company and as a Class III director of the Company, effective April 5, 2023.”
Kenneth Reali resigned as director at Bioventus Inc..
“On April 3, 2023, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) informed Kenneth Reali that it had determined that he would transition from his role as Chief Executive Officer of the Company and, on April 4, 2023, Mr. Reali resigned as a director and officer of the Company.”
Kenneth Reali resigned as Chief Executive Officer at Bioventus Inc..
“On April 3, 2023, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) informed Kenneth Reali that it had determined that he would transition from his role as Chief Executive Officer of the Company and, on April 4, 2023, Mr. Reali resigned as a director and officer of the Company.”
Bioventus Inc. reported financial results for the quarter and year ended December 31, 2022.
“On March 31, 2023 , Bioventus Inc. (the Company) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”
Bioventus Inc. entered into Settlement Agreement with CartiHeal (2009) Ltd., Elron Ventures Ltd. and certain other securityholders valued at $10,000,000 (effective 2023-02-27).
“On February 27, 2023, the Parties entered into a Settlement Agreement (the “Settlement Agreement”) under which the Securityholder Representative and LLC agreed and performed, in material part, as follows.”
John A. Bartholdson was appointed as Class II Director at Bioventus Inc..
“On January 8, 2023, the Board of Directors (the "Board") of Bioventus Inc. (the "Company") appointed John A. Bartholdson to the Board as a Class II director effective on January 8, 2023.”
Bioventus Inc. announced a restructuring with charges of between $4 million and $5 million of pre-tax costs.
“The Company expects to incur between $4 million and $5 million of pre-tax costs, of which $3 million to $4 million is due to employee severance and benefits, and the remaining $1 million is due to third-parties and other related costs.”
Bioventus Inc. reported the twelve months ending December 31, 2022 results: revenue $517 million to $522 million, EPS $0.20 to $0.25. Guidance lowered.
“• Net sales of $517 million to $522 million, representing year-over-year growth of approximately 20% to 21%, representing an update to the prior guidance of $547.5 million to $562.5 million. • Adjusted EBITDA* of $75 million to $79 million, compared to $80.8 million for the year ended December 31, 2021, and representing an update from the prior guidance of $94 million to $104 million. • Non-GAAP EPS* of $0.20 to $0.25, compared to $0.75 for the year ended December 31, 2021, and representing an update from the prior guidance of $0.47 to $0.57.”
Bioventus Inc. reported financial results for the nine months ended October 1, 2022.
“amended its previously announced financial results for the three and nine months ended October 1, 2022”
Bioventus Inc. reported the three months ended October 1, 2022 results: revenue $128.7 million, net income $145.7 million, EPS $1.76.
“• Net Sales of $128.7 million, up $19.8 million, or 18.2%, year-over-year as reported (19.1% constant currency*) and down (0.5%) organically* (0.3% constant currency*) • Net Loss of $145.7 million, compared to Net Loss of $2.3 million in prior-year period • Adjusted EBITDA* of $21.0 million, compared to $21.3 million in prior-year period • Loss per share of Class A common stock of $1.76, compared to $0.03 in prior-year period • Non-GAAP earnings per share of Class A common stock* of $0.06, compared to $0.19 in prior-year period”
Bioventus Inc. reported twelve months ending December 31, 2022 results: revenue $527 million to $532 million, EPS $0.20 to $0.25. Guidance lowered.
“Updated Full Year 2022 Financial Guidance: For the twelve months ending December 31, 2022, the Company now expects: • Net sales of $527 million to $532 million, representing year-over-year growth of approximately 22% to 23%, representing an update to the prior guidance of $547.5 million to $562.5 million.”
Bioventus Inc. reported three and nine months ended October 1, 2022 results: revenue $137.1 million, net income $3.2 million, EPS $0.03.
“in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights: • Net Sales of $137.1 million, up $28.2 million, or 25.9%, year-over-year as reported (26.8% constant currency*) and 7.3% organically* (8.1% constant currency*) • Net Income of $3.2 million, compared to Net”
Stavros G. Vizirgianakis resigned as Director at Bioventus Inc..
“On August 29, 2022, Stavros G. Vizirgianakis resigned as a member of the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”), effective as of that date.”
John E. Nosenzo retired as Chief Commercial Officer at Bioventus Inc..
“On June 27, 2022, John E. Nosenzo, Chief Commercial Officer of Bioventus Inc. (the “Company”), and the Company agreed on a transition plan providing for Mr. Nosenzo’s retirement from the Company, effective October 1, 2022.”
Gregory Anglum departed as Chief Financial Officer at Bioventus Inc..
“Mr. Anglum is expected to remain employed with the Company through April 2022, to assist with the transition.”
Mark Singleton was appointed as Senior Vice President, Chief Financial Officer and principal accounting officer at Bioventus Inc..
“On February 28, 2022, Bioventus Inc. (the “Company”) announced that Mark Singleton has been appointed as the Company’s Senior Vice President, Chief Financial Officer and principal accounting officer, effective March 21, 2022, succeeding Gregory Anglum in such role.”
Michelle McMurry-Heath was elected as Class I director at Bioventus Inc..
“On December 21, 2021, the Board elected Michelle McMurry-Heath as a Class I director of the Board for a term ending at the 2022 annual meeting of stockholders of the Company, effective on the Effective Date.”
David J. Parker resigned as Director at Bioventus Inc..
“On December 20, 2021, David J. Parker resigned as a member of the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”), effective as of January 1, 2022 (the “Effective Date”).”
Greg Anglum changed role as Senior Vice President and Chief Financial Officer at Bioventus Inc..
“On November 11, 2021, Bioventus Inc. (the “Company”) determined that Greg Anglum, the Company’s Senior Vice President and Chief Financial Officer and principal accounting officer, would transition from his role to pursue other career opportunities.”
Patrick J. Beyer was appointed as Director at Bioventus Inc..
“The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.”
Stavros G. Vizirgiankis was appointed as Director at Bioventus Inc..
“The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.”
Mary Kay Ladone was elected as Class II Director at Bioventus Inc..
“On July 12, 2021, the Board of Directors (the “Board”) of Bioventus Inc. (the “Company”) elected Mary Kay Ladone to the Board as a Class II director for a term ending at the 2023 annual meeting of stockholders of the Company, effective July 15, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.